NO308702B1 - Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav - Google Patents

Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav

Info

Publication number
NO308702B1
NO308702B1 NO960068A NO960068A NO308702B1 NO 308702 B1 NO308702 B1 NO 308702B1 NO 960068 A NO960068 A NO 960068A NO 960068 A NO960068 A NO 960068A NO 308702 B1 NO308702 B1 NO 308702B1
Authority
NO
Norway
Prior art keywords
magnesium omeprazole
preparation
pharmaceutical composition
composition containing
omeprazole
Prior art date
Application number
NO960068A
Other languages
English (en)
Norwegian (no)
Other versions
NO960068L (no
NO960068D0 (no
Inventor
Lars Ke Kollstroem
Monica Annelie Nygren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308702(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO960068L publication Critical patent/NO960068L/no
Publication of NO960068D0 publication Critical patent/NO960068D0/no
Publication of NO308702B1 publication Critical patent/NO308702B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Contacts (AREA)
  • Conductive Materials (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Powder Metallurgy (AREA)
  • Medicinal Preparation (AREA)
NO960068A 1993-07-09 1996-01-05 Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav NO308702B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form
PCT/SE1994/000680 WO1995001977A1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole

Publications (3)

Publication Number Publication Date
NO960068L NO960068L (no) 1996-01-05
NO960068D0 NO960068D0 (no) 1996-01-05
NO308702B1 true NO308702B1 (no) 2000-10-16

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960068A NO308702B1 (no) 1993-07-09 1996-01-05 Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav

Country Status (42)

Country Link
US (1) US5900424A (uk)
EP (2) EP1164132A3 (uk)
JP (2) JP3635432B2 (uk)
KR (1) KR100353783B1 (uk)
CN (1) CN1064680C (uk)
AT (1) ATE212628T1 (uk)
AU (1) AU679766B2 (uk)
BR (1) BR9406940A (uk)
CA (1) CA2166794C (uk)
CZ (1) CZ288933B6 (uk)
DE (2) DE707580T1 (uk)
DK (1) DK0707580T3 (uk)
DZ (1) DZ1792A1 (uk)
EE (1) EE03127B1 (uk)
EG (1) EG21437A (uk)
ES (1) ES2100136T3 (uk)
FI (1) FI114154B (uk)
GR (1) GR970300015T1 (uk)
HK (1) HK1008329A1 (uk)
HR (1) HRP940385B1 (uk)
HU (1) HU226861B1 (uk)
IL (1) IL110190A (uk)
IS (1) IS2075B (uk)
MA (1) MA23257A1 (uk)
MX (1) MX9405217A (uk)
MY (1) MY113274A (uk)
NO (1) NO308702B1 (uk)
NZ (1) NZ268693A (uk)
PL (1) PL175999B1 (uk)
PT (1) PT707580E (uk)
RU (1) RU2139868C1 (uk)
SA (1) SA94150058B1 (uk)
SE (1) SE9302396D0 (uk)
SG (1) SG52464A1 (uk)
SI (1) SI0707580T1 (uk)
SK (1) SK281230B6 (uk)
TN (1) TNSN94079A1 (uk)
TW (1) TW504509B (uk)
UA (1) UA43343C2 (uk)
WO (1) WO1995001977A1 (uk)
YU (1) YU49193B (uk)
ZA (1) ZA944933B (uk)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
CN1138534C (zh) * 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂
EE03378B1 (et) * 1994-07-08 2001-04-16 Astra Aktiebolag Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
PT1131316E (pt) * 1998-11-18 2004-10-29 Astrazeneca Ab Processo quimico e formulacao farmaceutica melhorados
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
BR0110926A (pt) * 2000-05-15 2004-02-17 Ranbaxy Lab Ltd Novas formas amorfas de sais de omeprazol e processo de preparação dos mesmos
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
DE69429774D1 (de) 2002-03-14
SG52464A1 (en) 1998-09-28
NO960068L (no) 1996-01-05
EG21437A (en) 2001-10-31
TW504509B (en) 2002-10-01
HU226861B1 (en) 2009-12-28
AU679766B2 (en) 1997-07-10
ES2100136T3 (es) 2002-09-01
SA94150058B1 (ar) 2006-06-20
BR9406940A (pt) 1996-09-10
CZ6996A3 (en) 1996-05-15
DK0707580T3 (da) 2002-04-15
CZ288933B6 (cs) 2001-09-12
JPH08512315A (ja) 1996-12-24
HUT75314A (en) 1997-05-28
YU43694A (sh) 1997-07-31
YU49193B (sh) 2004-09-03
SI0707580T1 (en) 2002-06-30
IL110190A0 (en) 1994-10-21
EP0707580A1 (en) 1996-04-24
UA43343C2 (uk) 2001-12-17
EP0707580B1 (en) 2002-01-30
JP2002105072A (ja) 2002-04-10
HRP940385A2 (en) 1997-02-28
FI960101A (fi) 1996-01-09
HK1008329A1 (en) 1999-05-07
CN1064680C (zh) 2001-04-18
GR970300015T1 (en) 1997-05-31
DE69429774T2 (de) 2002-11-14
MY113274A (en) 2002-01-31
AU7198194A (en) 1995-02-06
DZ1792A1 (fr) 2002-02-17
HU9503873D0 (en) 1996-02-28
CA2166794C (en) 1997-03-04
SE9302396D0 (sv) 1993-07-09
EP1164132A3 (en) 2002-01-02
HRP940385B1 (en) 2003-06-30
PL175999B1 (pl) 1999-03-31
EP1164132A2 (en) 2001-12-19
KR100353783B1 (ko) 2004-04-03
US5900424A (en) 1999-05-04
FI114154B (fi) 2004-08-31
ATE212628T1 (de) 2002-02-15
IS2075B (is) 2005-12-15
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
ES2100136T1 (es) 1997-06-16
IL110190A (en) 2000-07-26
WO1995001977A1 (en) 1995-01-19
MA23257A1 (fr) 1995-04-01
EE03127B1 (et) 1998-10-15
JP3635432B2 (ja) 2005-04-06
NO960068D0 (no) 1996-01-05
CN1126993A (zh) 1996-07-17
MX9405217A (es) 1995-01-31
IS4186A (is) 1995-01-10
TNSN94079A1 (fr) 1995-04-25
ZA944933B (en) 1995-02-20
JP3878826B2 (ja) 2007-02-07
FI960101A0 (fi) 1996-01-09
PT707580E (pt) 2002-06-28
DE707580T1 (de) 1997-09-04
NZ268693A (en) 1997-05-26
RU2139868C1 (ru) 1999-10-20
PL312440A1 (en) 1996-04-29

Similar Documents

Publication Publication Date Title
NO308702B1 (no) Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
AU4187093A (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
AU1413788A (en) Dihydropyridinamides process for their preparation, and their use in medicaments
HUT55033A (en) Process for producing aminooligohydroxy derivatives and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
MK1K Patent expired